Introduction Cangrelor is an intravenous P2Y12 inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis. [1] Cangrelor provides immediate platelet inhibition (onset within 2 minutes following administration of a 30 mcg/kg IV bolus, … [Read more...]